Can Imbruvica (Ibrutinib) Cause Interstitial Lung Disease?
Yes, Imbruvica (ibrutinib) can cause interstitial lung disease (ILD), as explicitly documented in the FDA drug label as a postmarketing adverse reaction. 1
Evidence from FDA Drug Label
The FDA prescribing information for Imbruvica clearly lists interstitial lung disease among postmarketing adverse reactions identified during post-approval use 1. This is the highest-quality evidence available, as drug labels represent regulatory-approved safety information based on comprehensive surveillance data.
Clinical Context and Significance
While the NCCN guidelines from 2015-2017 extensively detail ibrutinib's common adverse effects—including:
- Atrial fibrillation (6-9% incidence)
- Bleeding complications
- Hypertension
- Diarrhea
- Cytopenias
Notably, these guidelines do not mention pneumonitis or ILD 2, 3. This absence likely reflects that ILD is a rare but serious adverse event that emerged during broader post-approval surveillance rather than in controlled clinical trials.
Supporting Research Evidence
Published case reports and case series corroborate this risk:
A 2018 case series described severe life-threatening pneumonias in patients receiving ibrutinib monotherapy, with the authors hypothesizing a multifactorial etiology involving drug-induced pneumonitis, preexisting immunosuppression, and secondary infections 4
A 2019 case report documented a patient who developed interstitial pneumonia after restarting ibrutinib, suggesting drug-related pulmonary toxicity 5
A 2016 review of tyrosine kinase inhibitor-induced ILD noted that among 28 approved TKIs, 16 (57%) are reported to induce ILD with varying frequency, though ibrutinib was not specifically highlighted in this analysis 6
Clinical Management Recommendations
If ILD is suspected in a patient on ibrutinib:
- Immediately discontinue ibrutinib until thorough evaluation is complete
- Perform comprehensive diagnostic workup including:
- High-resolution chest CT
- Exclusion of infectious etiologies (bacterial, fungal, viral, including Pneumocystis)
- Assessment for disease progression
- Consideration of bronchoscopy with BAL if diagnosis remains unclear
- Initiate corticosteroids if drug-induced ILD is confirmed after excluding infection
- Do not rechallenge with ibrutinib if ILD is confirmed as drug-related
Important Caveats
- The diagnosis can be challenging in patients with preexisting pulmonary disease or underlying lymphoma with pulmonary involvement 4
- Patients with CLL/lymphoma on ibrutinib have baseline immunosuppression, making them susceptible to opportunistic infections that can mimic drug-induced pneumonitis 4
- The time course from drug initiation to ILD onset is unpredictable and can occur at any point during therapy 6
Bottom line: While ILD is not among ibrutinib's common adverse effects seen in clinical trials, it is a recognized postmarketing adverse reaction that requires immediate drug discontinuation and thorough evaluation to exclude infection before attributing symptoms to drug toxicity.